NASDAQ:CTOR Citius Oncology (CTOR) Stock Price, News & Analysis $0.94 -0.02 (-2.29%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Citius Oncology Stock (NASDAQ:CTOR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Citius Oncology alerts:Sign Up Key Stats Today's Range$0.91▼$0.9850-Day Range$0.49▼$1.1452-Week Range$0.49▼$6.19Volume48,252 shsAverage Volume240,866 shsMarket Capitalization$82.54 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ. Read More Citius Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreCTOR MarketRank™: Citius Oncology scored higher than 34% of companies evaluated by MarketBeat, and ranked 685th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCitius Oncology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCitius Oncology has a consensus price target of $6.00, representing about 527.0% upside from its current price of $0.96.Amount of Analyst CoverageCitius Oncology has received no research coverage in the past 90 days.Read more about Citius Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Citius Oncology is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Citius Oncology is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCitius Oncology has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Citius Oncology's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.15% of the float of Citius Oncology has been sold short.Short Interest Ratio / Days to CoverCitius Oncology has a short interest ratio ("days to cover") of 5.58.Change versus previous monthShort interest in Citius Oncology has recently decreased by 11.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCitius Oncology does not currently pay a dividend.Dividend GrowthCitius Oncology does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Citius Oncology this week, compared to 2 articles on an average week.MarketBeat Follows4 people have added Citius Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Citius Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders7.80% of the stock of Citius Oncology is held by insiders.Percentage Held by Institutions70.52% of the stock of Citius Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Citius Oncology's insider trading history. Receive CTOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Citius Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTOR Stock News HeadlinesCitius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® CommercializationMay 5 at 8:00 PM | prnewswire.comCitius Oncology Ships First International Order of LYMPHIR™ to EuropeApril 29, 2026 | prnewswire.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 6 at 1:00 AM | Brownstone Research (Ad)Citius Oncology Inc.April 28, 2026 | barrons.comBreakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)April 15, 2026 | finance.yahoo.comCitius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical DevelopmentMarch 31, 2026 | prnewswire.comCitius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma ExpertsMarch 24, 2026 | prnewswire.comCitius Oncology, Inc.: Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or ...March 10, 2026 | finanznachrichten.deSee More Headlines CTOR Stock Analysis - Frequently Asked Questions How have CTOR shares performed this year? Citius Oncology's stock was trading at $1.00 at the start of the year. Since then, CTOR shares have decreased by 4.3% and is now trading at $0.9569. How were Citius Oncology's earnings last quarter? Citius Oncology, Inc. (NASDAQ:CTOR) issued its quarterly earnings results on Friday, February, 13th. The company reported ($0.06) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.06). The business earned $3.94 million during the quarter, compared to analyst estimates of $4.37 million. How do I buy shares of Citius Oncology? Shares of CTOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Citius Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Oncology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Advanced Micro Devices (AMD), Broadcom (AVGO), Confluent (CFLT), Genius Sports (GENI) and Intel (INTC). Company Calendar Last Earnings2/13/2026Today5/06/2026Next Earnings (Estimated)5/20/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, CTOR's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTOR Previous SymbolNASDAQ:CTOR CIK1851484 Webwww.citiusonc.com Phone347-627-0058FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Citius Oncology$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+541.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.76 million Net MarginsN/A Pretax Margin-572.49% Return on Equity-55.19% Return on Assets-23.99% Debt Debt-to-Equity Ratio0.07 Current Ratio0.83 Quick Ratio0.32 Sales & Book Value Annual Sales$3.94 million Price / Sales20.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book1.73Miscellaneous Outstanding Shares88,275,000Free Float81,390,000Market Cap$82.54 million OptionableN/A Beta3.56 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CTOR) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersA U.S. Resource Gap Is a National Issue - and OpportunityAmerica still does not domestically produce one mineral tied to batteries, energy storage, and national defens...i2i Marketing Group, LLC | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredTrump and Elon are BACK15X Bigger Than SpaceX: Elon's New Launch While the rest of the market goes crazy for "the mother of all IP...InvestorPlace | SponsoredWhere the SpaceX "Tidal Wave" hits firstThe SpaceX and xAI IPO could trigger one of the largest capital shifts in market history — $1.75 trillion movi...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
